Nanofluidic drug-eluting seed for sustained intratumoral immunotherapy in triple negative breast cancer
Corrine Ying Xuan ChuaDepartment of Nanomedicine, Houston Methodist Research Institute (HMRI), Houston, TX, USAPriya JainDepartment of Nanomedicine, Houston Methodist Research Institute (HMRI), Houston, TX, USAAntonia SusnjarDepartment of Nanomedicine, Houston Methodist Research Institute (HMRI), Houston, TX, USAJessica RhudyDepartment of Nanomedicine, Houston Methodist Research Institute (HMRI), Houston, TX, USAMarco FolciDepartment of Allergy and Clinical Immunology, Istituto Auxologico Italiano, University of Milan, Milan, ItalyAndrea BalleriniDepartment of Nanomedicine, Houston Methodist Research Institute (HMRI), Houston, TX, USA; Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, ItalyApril L. GilbertDepartment of Nanomedicine, Houston Methodist Research Institute (HMRI), Houston, TX, USAShailbala SinghDepartment of Melanoma Medical Oncology, University of MD Anderson Cancer Center, Houston, TX, USAGiacomo BrunoDepartment of Nanomedicine, Houston Methodist Research Institute (HMRI), Houston, TX, USA; Politecnico di Torino, Turin, ItalyCarly S. FilgueiraDepartment of Nanomedicine, Houston Methodist Research Institute (HMRI), Houston, TX, USACassian YeeDepartment of Melanoma Medical Oncology, University of MD Anderson Cancer Center, Houston, TX, USAE. Brian ButlerDepartment of Radiation Oncology, Houston Methodist Hospital, Houston, TX, USAAlessandro GrattoniDepartment of Nanomedicine, Houston Methodist Research Institute (HMRI), Houston, TX, USA; Department of Radiation Oncology, Houston Methodist Hospital, Houston, TX, USA; Department of Surgery, Houston Methodist Hospital, Houston, TX, USA. Electronic address: [email protected]
2018en
ABI
Аннотация
Аннотация отсутствует.
Идентификаторы
Цитирования и источники
Цитирований: 4Использованных источников: 0